3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
202
Leukemia, Lymphocytic, Chronic, B-Cell
54
Recurrence
37
Neoplasms, Plasma Cell
30
Lymphoma, Mantle-Cell
30
Lymphoma
30
Lymphoma, Follicular
29
Lymphoma, Large B-Cell, Diffuse
27
Leukemia
23
Leukemia, Myeloid, Acute
22
Lymphoma, Non-Hodgkin
21
Lymphoma, B-Cell, Marginal Zone
15
Myelodysplastic Syndromes
13
Hodgkin Disease
12
Waldenstrom Macroglobulinemia
8
Prostatic Neoplasms
8
Lymphoma, T-Cell
8
Smoldering Multiple Myeloma
7
Immunoglobulin Light-chain Amyloidosis
7
Neoplasms
6
Melanoma
6
Lymphoma, B-Cell
6
Hematologic Diseases
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large-Cell, Anaplastic
5
Leukemia, Myelomonocytic, Chronic
5
Hematologic Neoplasms
5
Amyloidosis
5
Sezary Syndrome
4
Interventions
Bortezomib
3
fludarabine phosphate
2
Cyclophosphamide
2
Busulfan
2
Bendamustine Hydrochloride
2
tetulomab tetraxetan lu-177
1
ponatinib
1
pembrolizumab
1
ibrutinib
1
durvalumab
1
acalabrutinib
1
Vorinostat
1
Telemedicine
1
Tacrolimus
1
Rituximab
1
Mycophenolic Acid
1
Lymphocyte Depletion
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Hsp90 inhibitor KU757
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Immune System Diseases
×
Lenalidomide
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts